Our NephJC NOSTONE editorial in Kidney Medicine is live. Great work from Renz Palisan, Nikita Pawar, and Rasha Alawieh; supported by Swap and Jade.
Read it here.
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
This week, we will discuss a phase 2 trial of the TRPC6 inhibitor BI 764198 in FSGS—an early signal for a podocyte-targeted therapy showing proteinuria reduction but set against small numbers, heterogeneity, and methodological trade-offs that frame this as direction-finding rather than definitive evidence.
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
Our NephJC NOSTONE editorial in Kidney Medicine is live. Great work from Renz Palisan, Nikita Pawar, and Rasha Alawieh; supported by Swap and Jade.
Read it here.
Thiazides to prevent rolling stones - the Ten Tweet summary of NOSTONE is here.
Welcome to #TenTweetNephJC - we’re again covering a practice changing trial, but unfortunately one that shows a treatment we’ve prescribed for decades for kidney stone prevention ain’t doing a huge amount....🧵 pic.twitter.com/j23gn9grw1
— Nephrology Journal Club (@NephJC) May 3, 2023
Check out the crisp VA on NOSTONE trial by Renz Pasilan
What’s your loop and thiazide of choice? Do you know which diuretics are better, faster, stronger? This week’s TenTweets is a two-fer (Chlorthalidone vs HCTZ and Furosemide vs Torsemide). Tweetorial catch-up here.
Welcome to #TenTweetNephJC
— Nephrology Journal Club (@NephJC) February 10, 2023
✳️10 tweets #NephJC catch-up ✳️
We all have our “go to” diuretics that are better, faster, stronger…but are they?
What evidence is there that one diuretic (in a class) is superior to another for CV outcomes?
It’s a 2-fer TenTweets.
Let’s go… pic.twitter.com/9Ms3zg8Z5z